Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care

Trial Profile

Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Brodalumab (Primary) ; Interleukin-17 inhibitors
  • Indications Psoriasis
  • Focus Adverse reactions
  • Sponsors Ortho Dermatologics; Valeant Pharmaceuticals International
  • Most Recent Events

    • 06 Apr 2018 Planned initiation date changed from 15 Mar 2018 to 15 Sep 2018.
    • 21 Aug 2017 New trial record
    • 27 Jul 2017 According to Valeant Pharmaceuticals International media release, Valeant Pharmaceuticals International renamed its dermatolgy unit as Ortho Dermatologics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top